Chimeric antigen receptor T cell therapy reduces vaccine immunity, with many patients lacking seroprotection despite stable antibody levels.
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable ...
Massive hepatic necrosis (MHN) represents the most severe pathological form of acute liver failure (ALF), with high mortality ...
MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial . Totality of efficacy and safety data re ...
Phase 2 trial data have shown that the CD38-targeting antibody mezagitamab can rapidly restore platelet counts in immune ...
Study has shown that obesity impairs antibody durability through germinal centre dysfunction while enhancing lung-resident ...
The research group of Prof. Sanjiv Luther at the Department of Immunobiology of the University of Lausanne has discovered ...
The research group of prof. Sanjiv Luther at the department of immunobiology of the University of Lausanne has discovered ...
Researchers at the School of Medicine at the University of California, Riverside have discovered previously unrecognized ...
Researchers at the School of Medicine at the University of California, Riverside have discovered previously unrecognized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results